Cancer News and Research

Latest Cancer News and Research

Affymax receives $244,479.25 in funding under QTDP program

Affymax, Inc. today announced that it has been awarded $244,479.25 in funding under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program established under Section 48D of the Internal Revenue Code.

4 Nov 2010

PolyMedix receives $488,958 grants under QTDP program

PolyMedix, Inc. a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced today that it has been awarded two cash grants totaling $488,958 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

Regulus receives $488,989 grant under QTDP program

Regulus Therapeutics Inc. announced today that it has been awarded two grants totaling $488,989 under the Federal government's Qualifying Therapeutic Discovery Project Program.

4 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

One-third of breast cancer survivors rate breast-conserving treatments as fair

A third of breast cancer survivors who received the breast-conserving treatments lumpectomy and radiation rate the appearance of their post-treatment breast as only "fair" or "poor" in comparison to their untreated breast, according to a new University of Pennsylvania School of Medicine study that will be presented today at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.

3 Nov 2010

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

ADVENTRX submits NDA for Exelbine to FDA

ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine.

3 Nov 2010

First Edition: November 3, 2010

Today's headlines track the GOP's sweeping electoral gains and begin to explore what this power shift might mean for the future of the health law.

3 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

Ingenuity Systems and Geospiza partner to enable seamless next-generation sequencing analysis workflow

Ingenuity® Systems, a leading provider of information solutions for life science researchers, and Geospiza, Inc., the market leading developer of laboratory management and genetic analysis software, today announced a collaboration to enable a seamless next-generation sequencing analysis workflow. The companies will integrate their software products, GeneSifter® and IPA®, to enable researchers to obtain deep biological insights from their project samples through a rapid and reliable workflow to analyze and visualize next-generation sequencing data.

3 Nov 2010

GTx receives $1.2 million under QTDP program

GTx, Inc. announced that the company has been awarded approximately $1.2 million by the United States Government under the Qualifying Therapeutic Discovery Project Program (QTDP), a $1 billion fund established under HR: 3590 Patient Protection and Affordable Care Act.

3 Nov 2010

EUSA announces publication of PROSTASCINT imaging for prostate cancer in official journal of American Society

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT (capromab pendetide) fusion imaging is an effective tool for targeting and guiding the dosing of prostate cancer radiotherapy.

3 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

InVivo receives $244,000 in grant funding under QTDP program

InVivo Therapeutics a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has been awarded $244,000 in grant funding as part of the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

3 Nov 2010

Radiation oncologist says radiation quality assurance practices need to be standardized

In 2009, after The New York Times reported a series of mistakes in radiation therapy delivery, a team of radiation oncologists at the Kimmel Cancer Center at Jefferson decided to investigate how thoroughly different hospitals use "chart rounds" to review the radiotherapy cancer patients receive.

3 Nov 2010

Deloitte releases new report on innovative strategies for oncology drug development

Deloitte released a new report, "Innovative Strategies for Oncology Drug Development," highlighting specific drug development approaches that have enabled biotech companies to produce a substantial number of first-in-class compounds and more than $1 billion in oncology drugs while transforming the medical outlook for many cancer patients.

3 Nov 2010

Labor-HHS bill to provide 3.2% increase in fiscal year 2011 for NIH

Despite innovative cancer research being presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, as well as numerous other conferences organized by the American Association for Cancer Research each year, the pace of scientific discovery in cancer research will slow if Congress does not pass the pending appropriations bill for fiscal year 2011.

3 Nov 2010

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Immune Network Ltd. a company in the business of discovery and development of immune-based therapies, today announced that patient enrollment will be completed next week for the company's future partner Immunitor's Phase 2b imm01 trial of V5 immunotherapy in 120 patients with tuberculosis.

3 Nov 2010

Allen Institute releases new data and tools for exploring genes at work in human brain

The Allen Institute for Brain Science announced today its twentieth public data release, which includes new data and tools for exploring genes at work in the human brain. In addition to expanding and enhancing the Allen Human Brain Atlas, the Allen Institute launched two new human brain resources: the Ivy Glioblastoma Atlas Project and the NIMH Transcriptional Atlas of Human Brain Development.

3 Nov 2010

EUREKA program confirms ability of HIFU technology to deliver cancer drugs

EDAP TMS SA the global leader in therapeutic ultrasound, reported today successful completion of feasibility studies aimed at improving delivery of cancer drugs using a combination of ultrasound sensitive liposomes and High Intensity Focused Ultrasound (HIFU).

3 Nov 2010